Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6873239

N=C(N)c1ccc(O)c(OCCNC(=O)c2ccc(OC3CCNCC3)cc2)c1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
F10 P00742 18/20 0.57
F2 P00734 6/20 0.54
PDE4A P27815 2/20 0.42
PDE4B Q07343 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
PLG P00747 1/20 0.39
PROC P04070 1/20 0.39
KLK1 P06870 1/20 0.39
PRSS1 P07477 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3896028 0.87 F10 (0.68) F10F2PLGPROCKLK1
Trifluoroacetic Acid SCHEMBL6873840 0.87 F10 (0.76) F10F2PRSS1
Trifluoroacetic Acid SCHEMBL6553710 0.86 F10 (0.61) F10F2PDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL6553830 0.85 F10 (0.51) F10F2PDE4APDE4BPDE4C
SCHEMBL14132033 0.83 F10 (0.77) F10F2PDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL6857478 0.83 F10 (0.59) F10F2PDE4APDE4BPDE4C
SCHEMBL14132040 0.81 F10 (0.74) F10F2PLGPROCKLK1
SCHEMBL6555792 0.80 F10 (0.62) F10F2PDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL3897211 0.78 F10 (0.70) F10F2PDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL6771145 0.77 ROCK1 (0.48) F10F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812231-B2 INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20020107290-A1 Benzamidine derivative AJINOMOTO CO., INC. (JP) 2002-08-08 US disclosed
US-6410538-B2 ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI AJINOMOTO CO., INC. (JP) 2002-06-25 US disclosed
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli AJINOMOTO CO., INC (JP) 2001-12-27 US disclosed
EP-1086946-A1 BENZAMIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107290-A1 Benzamidine derivative SERPINE1, SERPINC1, TFPI F10 21/4885F2 6/4885PDE4A 2085/4885
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli SERPINC1, SERPINE1, F2 F10 16/4885F2 3/4885PDE4A 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.